Alto Neuroscience (ANRO) Financials

Alto Neuroscience (NYSE: ANRO) continues to operate as a pre-revenue biotech company, with no reported revenue across the last several years and persistent operating losses. The latest Q1 2026 results show another quarter of heavy R&D spending, but the company also ended the period with a very strong cash position after sizable financing inflows. For retail investors, the key question is not near-term profitability, but whether Alto can advance its pipeline efficiently enough to justify the cash burn and eventual dilution risk.

• Cash balance is substantial. Alto reported $263.8 million in cash and equivalents at the end of Q1 2026, up sharply from $160.8 million a year earlier and $137.8 million in Q3 2025.
• The balance sheet remains asset-heavy and liquid. Total current assets of $269.1 million far exceed total liabilities of $32.9 million, giving the company a strong short-term liquidity profile.
• Operating cash runway improved recently. Q1 2026 net cash from financing activities was $114.9 million, helping offset ongoing operating losses and increase the cash balance.
• Interest income is helping offset losses. In Q1 2026, Alto generated $1.56 million of interest and investment income, which partially cushioned the pre-tax loss.
• Capital spending remains modest. Q1 2026 purchases of property, plant and equipment were only $556,000, indicating the company is not heavily burdened by capital expenditures.
• No revenue has been reported. Revenue was $0 in every period provided, so Alto remains dependent on financing and pipeline progress rather than product sales.
• R&D spending remains the core use of cash. Q1 2026 research and development expense was $20.3 million, consistent with a clinical-stage biotech focused on development rather than commercialization.
• SG&A costs are also significant. Q1 2026 selling, general and administrative expense was $6.8 million, showing meaningful overhead alongside research spending.
• Interest-bearing debt is present but manageable for now. Q1 2026 showed $16.0 million in total debt split between short-term and long-term borrowings, which is small relative to cash on hand.
• Losses remain large. Q1 2026 net loss was $26.2 million, wider than the $16.2 million loss in Q4 2025 and the $15.2 million loss in Q1 2025.
• Operating cash burn is still substantial. Q1 2026 operating cash flow was negative $27.1 million, compared with negative $11.5 million in Q4 2025 and negative $16.6 million in Q1 2025.
• Share count has risen meaningfully over time. Weighted average basic shares were 32.9 million in Q1 2026 versus 27.0 million in Q1 2025, suggesting ongoing dilution pressure.
• Equity has fallen from prior highs. Total common equity dropped to $243.4 million in Q1 2026 from $165.1 million in Q3 2024 after major financing and loss accumulation changes, reflecting a business still in a cash-intensive development phase.

Trend summary: Over the past four years, Alto Neuroscience has consistently posted operating losses with no revenue, while cash balances have fluctuated depending on financing events. The most important positive takeaway is the current cash position, which gives the company flexibility to continue advancing its pipeline. The main risk remains the same: until clinical progress translates into either partnering revenue or commercialization, Alto will likely keep burning cash and may need to raise more capital in the future.